Sagimet Biosciences INC Form 4 insider transactions

George Kemble, a Director of Sagimet Biosciences Inc., sold 20,206 shares of common stock on August 11, 2026 for $9.95 per share.

David Happel, President & CEO and a Director of Sagimet Biosciences Inc., sold 64,051 shares of common stock on July 20, 2026 for $7.76 per share.

Elizabeth Rozek, Chief Legal & Admin. Officer of Sagimet Biosciences Inc., sold 10,545 shares of common stock on July 20, 2026 for $7.76 per share.

George Kemble, a Director of Sagimet Biosciences Inc., sold 18,844 shares of common stock on July 20, 2026 for $7.46 per share.

Director Beth Seidenberg acquired stock options for 39,567 shares of Sagimet Biosciences Inc. (SGMT) on June 12, 2026, with an exercise price of $6.48.

Paul W. Hoelscher, a Director at Sagimet Biosciences Inc., acquired stock options for 39,567 shares of Series A Common Stock.

Jennifer Jarrett, a Director at Sagimet Biosciences Inc., acquired stock options for 39,567 shares.

Elizabeth A. Grammer, a Director at Sagimet Biosciences Inc., acquired stock options for 39,567 shares.

George Kemble, a Director at Sagimet Biosciences Inc., acquired stock options for 39,567 shares of Series A Common Stock.

Anne M. Phillips, a Director at Sagimet Biosciences Inc., acquired stock options for 39,567 shares.

Sagimet Biosciences CFO Thierry Chauche was granted 50,000 stock options as part of an equity incentive plan.

Chief Medical Officer Andreas Grauer was granted 35,000 stock options in Sagimet Biosciences Inc. as part of an equity incentive.

Chief Legal & Admin. Officer Elizabeth Rozek was granted 100,000 stock options in Sagimet Biosciences Inc.

Sagimet Biosciences CEO David Happel was granted 300,000 stock options as part of his compensation package.

Sagimet Biosciences' Chief Medical Officer, Andreas Grauer, was granted 264,759 stock options with an exercise price of $6.44.

Sagimet Biosciences CEO David Happel sold 12,101 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Sagimet Biosciences Chief Financial Officer Thierry Chauche sold 1,312 shares of Series A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Sagimet Biosciences Chief Legal & Admin. Officer Elizabeth Rozek sold 2,622 shares of Series A Common Stock to cover tax withholding obligations.

Sagimet Biosciences Inc.'s Executive Chairman, George Kemble, sold 37,688 shares of Series A Common Stock for a weighted average price of $7.6942 per share, executed under a pre-arranged 10b5-1 trading plan.

Sagimet Biosciences Inc. granted restricted stock units and stock options to Elizabeth Rozek following her promotion to Chief Legal & Administrative Officer.

Sagimet Biosciences Inc.'s President and CEO, David Happel, sold 65,478 shares of Series A Common Stock at $9.1346 per share to cover tax withholding obligations related to restricted stock unit vesting.

Sagimet Biosciences' Chief Medical Officer, Eduardo Bruno Martins, sold 8,277 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Sagimet Biosciences' General Counsel and Chief Compliance Officer, Elizabeth Rozek, sold 10,780 shares of Series A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Sagimet Biosciences Inc. director Timothy P. Walbert was granted 32,250 stock options with an exercise price of $5.33, vesting over 12 equal monthly installments starting June 9, 2025.

Sagimet Biosciences Inc. Director Beth C. Seidenberg was granted a total of 60,772 stock options with vesting periods tied to continued service, as disclosed in a recent SEC Form 4 filing.

Sagimet Biosciences Inc. director Anne M. Phillips was granted 27,268 stock options with an exercise price of $5.33, vesting monthly over one year.

Sagimet Biosciences Inc. director George Kemble was granted 32,250 stock options with an exercise price of $5.33, vesting over 12 months starting June 9, 2025.

Sagimet Biosciences Inc. Director Jennifer Jarrett has been granted stock options to acquire 27,268 shares of common stock at an exercise price of $5.33 per share, vesting over 12 months.

Sagimet Biosciences Inc. Director Paul W. Hoelscher was granted 32,250 stock options with an exercise price of $5.33, vesting over 12 months starting June 9, 2025.

Sagimet Biosciences Inc. Director Elizabeth A. Grammer has acquired 32,250 stock options with an exercise price of $5.33, vesting monthly over one year.